Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axogen (AXGN) Long-Term Debt Issuances (2010 - 2012)

Axogen's quarterly Long-Term Debt Issuances came in at $14.2 million in Q4 2012, up 89.48% quarter-over-quarter from $7.5 million in Q3 2011.

Axogen has reported Long-Term Debt Issuances for 3 years, with the latest figure at $14.2 million in Q4 2012.

  • For the quarter ending Q4 2012, Long-Term Debt Issuances changed N/A year-over-year to $14.2 million; the trailing twelve-month figure through Sep 2021 stood at $14.2 million (down 34.54% YoY), and the FY2021 full-year result was $15.0 million, up 91.82% from the prior year.
  • Long-Term Debt Issuances for Q4 2012 stood at $14.2 million, up from $7.5 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $14.2 million in Q4 2012, with the low at $2.4 million in Q4 2010.
  • Average Long-Term Debt Issuances over 3 years is $8.0 million, with a median of $7.5 million recorded in 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Axogen 2.00 Bn 1.90 Bn 46.19 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 14.21 Mn
Dec 31, 2012 14.21 Mn
Sep 30, 2011 7.50 Mn
Sep 30, 2011 7.50 Mn
Dec 31, 2010 2.38 Mn
Dec 31, 2010 2.38 Mn